AOD-9604 vs Semaglutide
Both AOD-9604 and Semaglutide are used for weight-loss. Here's how their evidence, dosing, and regulatory status actually compare.
AOD-9604
Evidence C+Anti-Obesity Drug 9604
A modified fragment of human growth hormone (hGH 176-191) that stimulates fat breakdown without the growth-promoting or diabetogenic effects of full HGH.
View full AOD-9604 profile →Semaglutide
Evidence A+Semaglutide (Ozempic / Wegovy)
A GLP-1 receptor agonist and the gold standard for evidence-based weight loss peptide therapy. Demonstrated 14.9–16.9% mean body weight reduction in the landmark STEP trials.
View full Semaglutide profile →Side-by-Side
| Attribute | AOD-9604 | Semaglutide |
|---|---|---|
| Evidence Grade | C+ | A+ |
| FDA Status | Not FDA-approved — Category 1 (compounding allowed) | FDA-approved for weight management and type 2 diabetes |
| Typical Dose | 250–500 mcg daily (subcutaneous) | 0.25–2.4 mg weekly (subcutaneous injection) |
| Clinics Indexed | 134 | 2,285 |
| Categories | weight-loss, fat-loss | weight-loss, metabolic |
Key reported benefits — AOD-9604
- ✓Fat metabolism
- ✓No HGH side effects
- ✓Cartilage repair potential
Key reported benefits — Semaglutide
- ✓Significant weight loss
- ✓Appetite suppression
- ✓Blood sugar control
- ✓Cardiovascular benefit
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.